度伐利尤单抗影响无进展生存,而总放疗剂量>66 Gy可改善不可切除Ⅲ期非小细胞肺癌的局部控制且不增加毒性:来自奥地利放射肿瘤肺癌研究协会登记处(ALLSTAR)的真实世界数据
ALLSTAR前瞻性多中心登记研究纳入188例不可切除Ⅲ期非小细胞肺癌患者,按本地实践行放化疗联合免疫治疗。接受度伐利尤单抗者中位无进展生存25.8个月,未接受者为15.7个月(HR=1.88)。总放疗剂量>66 Gy者2年局部控制率86%,≤66 Gy者为60%(HR=0.41),未增加毒性。
要点
- 度伐利尤单抗组中位无进展生存25.8个月,未使用者15.7个月(HR=1.88,95%CI 1.16-3.05,log-rank P<0.01)。
- 总剂量>66 Gy组2年局部控制率86%,≤66 Gy组60%(HR=0.41,95%CI 0.17-0.98,log-rank P<0.05)。
- >66 Gy亚组75例中25%(19例)出现1-3级肺毒性,未观察到超额毒性。
核心结论
- 度伐利尤单抗影响无进展生存,总放疗剂量>66 Gy可改善局部控制且不增加毒性。
研究设计与样本
- 奥地利放射肿瘤肺癌研究协会登记处(ALLSTAR)为前瞻性多中心登记研究,旨在记录度伐利尤单抗时代临床实践。
- 2020年3月至2023年4月,12/14(86%)家奥地利放射肿瘤中心共纳入188例经病理证实的不可切除Ⅲ期非小细胞肺癌且具根治治疗机会的患者(中位17例,范围1-89)。
- 放化疗联合免疫治疗按本地治疗实践执行,终点为局部控制、无进展生存和毒性。
主要发现
- 173/188(93%)患者进行了PD-L1检测;放化疗结束至度伐利尤单抗开始的中位间隔为14天(范围1-65)。
- 75/188(约40%)患者接受总放疗剂量>66 Gy(范围67.1-100 Gy),其2年局部控制率86% vs 60%(HR=0.41,95%CI 0.17-0.98,log-rank P<0.05)。
- 接受度伐利尤单抗者中位无进展生存25.8个月(95%CI 21.9-未达到),未接受者15.7个月(95%CI 13.2-27.8),HR=1.88(95%CI 1.16-3.05,log-rank P<0.01)。
- 食管毒性和肺毒性发生率分别为34.6%和23.9%,包括1例4级肺炎。
- 接受>66 Gy的75例亚组中,观察到19例(25%)1-3级肺毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemo-radioimmunotherapy with total radiation doses of 60-66 Gy in 2 Gy fractions is the standard of care for non-small cell lung cancer (NSCLC) UICC stage III. The Austrian radio-oncological lung cancer study association registry (ALLSTAR) is a prospective multicentre registry intended to document clinical practice at the beginning of the Durvalumab era. PATIENTS AND METHODS: Patients were eligible if they had pathologically verified unresectable NSCLC stage III with a curative treatment option. Chemo-radiation combined with immunotherapy was performed according to local treatment practices. The endpoints were local control (LC), progression-free survival (PFS) and toxicity. RESULTS: Between 2020/03 and 2023/04, 12/14 (86 %) Austrian radiation-oncology centres recruited 188 patients (median 17, range: 1-89). PD-L1 testing was performed in 173/188 (93 %) patients. The median interval between the end of chemoradiotherapy and start of Durvalumab was 14 days (range: 1-65). About 40 % (75/188) of the patients received a total radiation dose of > 66 Gy (range: 67.1-100), which improved 2-year LC (86 % versus 60 %, HR = 0.41; 95 %-CI: 0.17-0.98; log-rank p-value < 0.05). Median PFS for patients with Durvalumab was 25.8 months (95 %-CI: 21.9-not reached) compared to 15.7 months (95 %-CI: 13.2-27.8) for those without (HR = 1.88; 95 %-CI: 1.16-3.05; log-rank p-value < 0.01). The rates of esophageal and pulmonary toxicities were 34.6 % and 23.9 %, respectively, including one case of grade 4 pneumonitis. In the subcohort of 75 patients who received > 66 Gy, 19 (25 %) cases of pulmonary toxicity grades 1-3 were observed. CONCLUSION: While Durvalumab impacts PFS, LC can be improved by total radiation doses > 66 Gy without excess toxicity.
引用
- Zehentmayr F, Feurstein P, Ruznic E, et al. Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR). Radiother Oncol. 2024. PMID: 38653380. doi:10.1016/j.radonc.2024.110294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。